Clinical Trial Update: Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 trial results update describing the efficacy, safety and tolerability of CX157 in treatment-resistant depression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Depression

Drugs mentioned

• CX157

Snippet

Sponsor: CeNeRx BioPharma Inc. | Conditions: Treatment Resistant Depression | Phase 2 | Status: COMPLETED